TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05088226
Drug: Ruxolitinib combined with Chidamide.
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide .~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI , Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;
Study: NCT05640817
Drug: Pentoxifylline 400 mg SR tablets
Normalized name: pentoxifylline 400 MG
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a nonspecific phosphodiesterase inhibitor, was first considered in the treatment of peripheral vascular diseases
Study: NCT05640817
Drug: cisplatin with standard hydration with normal saline
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT05226754
Drug: Diacerein
Normalized name: diacerein
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After enrolment, patients will be randomized (n=20 group A) to receive diacerein capsules 50 mg every 12 hours for 10 days.
Study: NCT05068388
Drug: Z-Endoxifen
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z-Endoxifen
Study: NCT05532254
Drug: Aripiprazole 10 mg tablet
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: an immediate-release tablet containing 10 mg Aripiprazole
Study: NCT04890561
Drug: Lemborexant
Normalized name: Lemborexant
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lemborexant oral tablets.
Study: NCT05074498
Drug: TB006
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous infusion
Study: NCT06630923
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.
Study: NCT06631612
Drug: ferric hydroxide polymaltose complex
Normalized name: ferric hydroxide
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will receive oral iron supplementation according to body weight every other day
Study: NCT06631612
Drug: ferric hydroxide polymaltose complex
Normalized name: ferric hydroxide
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will receive oral iron supplementation dose according to body weight daily
Study: NCT04844099
Drug: Dihydroartemisinin Piperaquine
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
Study: NCT05887817
Drug: Finerenone
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
Study: NCT05104788
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05104788
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
Study: NCT05104788
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles
Study: NCT05070104
Drug: CPI-613
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-1000mg/m2 -14 day cycle
Study: NCT05070104
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg/kg IV
Study: NCT05104788
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 2 cycles
Study: NCT04701060
Drug: Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
Study: NCT05000450
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for lymphodepletion
Study: NCT06278857
Drug: Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]
Normalized name: Dostarlimab-gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The dosing regimen follows standard clinical care protocol comprising of 4 cycles every 3-weeks, a rest period of 34 weeks followed by 3 cycles every 6 weekly for a total of 7 cycles.
Study: NCT04874610
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of methylprednisolone Prescribed per Standard of care
Study: NCT06400056
Drug: Terbinafine
Normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved
Study: NCT05000892
Drug: Sintilimab , Carboplatin, Nab-paclitaxel
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive Sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
Study: NCT05274984
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the experimental group will be given 1.5mg/kg lidocaine and then 2mg/kg/h
Study: NCT05062083
Drug: 11C-MC1
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 20 mCi injected IV followed by PET scanning
Study: NCT05062083
Drug: 11C-PS13
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 20 mCi injected IV followed by PET Scanning
Study: NCT05424003
Drug: Semaglutide Pen Injector
Normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose of 0.24 mg injected weekly and increased every 4 weeks to a potential maximum dose of 2.4 mg weekly at 20 weeks followed by 52 weeks of weekly injections at the maximum tolerable dose
Study: NCT06629415
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: injecting 7.5 mg (3 ml of a 25 mg/10 ml solution) intravenously in the pre-operative holding area at least 20 minutes before surgery.~Before dissecting the adhesions surrounding the hepatoduodenal ligament, fluorescence cholangiography (FC) is carried out to determine the anatomy of the extrahepatic bile ducts by converting the full-color images to fluorescence images using filter switches on the camera head and/or light source in the laparoscopic imaging system (Fig. 1). The \&amp;#34;critical view of safety\&amp;#34; is then reached by dissecting Calot\&amp;#39;s triangle and using FC to verify whether the accessory bile ducts are present or absent throughout the procedures. It is necessary to acquire fluorescence image
Study: NCT06629415
Drug: Indocyanine Green Drug
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.25 mg of ICG powder was dissolved in 3 cm of saline, and the concentration was roughly 0.04 mg after each 1 cm of saline was diluted by 9 cm of saline. In order to prevent dye leakage that might result in false FC results, a veress needle was inserted through the abdominal wall and into the gall bladder fundus through the liver bed. The puncture site was then cauterized.
Study: NCT04563338
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Atezolizumab binds to PD-L1 which is a protein involved preventing the body's immune system (defense system against infection and disease) from fighting cancer cells. Blocking PD-L1 is expected to help the immune cells to destroy the cancer cells.
Study: NCT04563338
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Bevacizumab binds to vascular endothelial growth factor (VEGF) which is a protein involved with the growth of new blood vessels. Blocking VEGF will prevent blood vessels from forming and therefore stopping oxygen and nutrients to be supplied to cancer cells. Without oxygen and nutrients, the cancer cells will die.
Study: NCT06462781
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-arterial injection of 40mg lidocaine per middle meningeal artery (total 2 arteries) administered one time
Study: NCT06462781
Drug: Methylprednisolone sodium succinate
Normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-arterial injection of 20mg methylprednisolone per middle meningeal artery (total 2 arteries) administered one time
Study: NCT03826693
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
Study: NCT03826693
Drug: Nitrogen
Normalized name: Nitrogen
DrugBank: Nitrogen (DB09152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
Study: NCT05373264
Drug: Hydrochlorothiazide 25 mg
Normalized name: hydrochlorothiazide 25 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An oral capsule containing 25mg of hydrochlorothiazide
Study: NCT04606264
Drug: Perphenazine
Normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This randomized group will receive 8 mg of perphenazine orally preoperatively.
Study: NCT04606264
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This randomized group will receive 40 mg of aprepitant orally preoperatively.
Study: NCT04606264
Drug: Dimenhydrinate
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.
Study: NCT04606264
Drug: Ondansetron 4 MG
Normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This randomized group will receive 4 mg of ondansetron orally.
Study: NCT04606264
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This randomized group will receive 4-5 mg of dexamethasone intravenously.
Study: NCT04656002
Drug: Vactosertib
Normalized name: Vactosertib
DrugBank: Vactosertib (DB15310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours
Study: NCT05173493
Drug: Amoxicillin,Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin-Furazolidone-containing quadruple group
Study: NCT05173493
Drug: Amoxicillin,Levofloxacin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin-Levofloxacin-containing quadruple group
Study: NCT06630416
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT04905316
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Intravenous Canakinumab (ACZ885) should start no sooner than 3 weeks after the last subcutaneous Canakinumab (ACZ885) injection. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.
Study: NCT04905316
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with durvalumab either at a dose of 10mg per kilogram of body weight intravenously every 2 weeks or at a 1500 mg fixed dose administered every 4 weeks as consolidation therapy after completion of concurrent chemoradiation therapy, as per standard of care.
Study: NCT05648526
Drug: ACTH4-10Pro8-Gly9-Pro10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis
Study: NCT05648526
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: negative-positive control (ketamine 40 mg/kg BW subcutaneously)
Study: NCT05377619
Drug: Prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: prucalopride 2 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
Study: NCT05377619
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: buspirone 10 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
Study: NCT06109207
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery
Study: NCT06109207
Drug: Dalpiciclib 100mg
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
Study: NCT06109207
Drug: Dalpiciclib 150mg
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
Study: NCT06363539
Drug: Clobetasol Propionate .05 Mg in 100 mL TOPICAL LOTION
Normalized name: Clobetasol Propionate .05 mg in 100 mL TOPICAL LOTION
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: steroid used for umblical granuloma
Study: NCT06363539
Drug: Silver Nitrate
Normalized name: Silver Nitrate
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: silver nitrate used for treatment
Study: NCT04530409
Drug: Early-Corticosteroids
Normalized name: abiraterone and corticosteroids
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: early use of dexamethasone/Methylprednisolone as early as laboratory evidence of high inflammatory markers
Study: NCT04780464
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-20 mg on day 1 to day 7 of each 14 day cycle until PD for those Countries where Prednisolone in tablets is not available
Study: NCT04745767
Drug: TAK-994
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T2 formulation.
Study: NCT04745767
Drug: TAK-994
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1 formulation.
Study: NCT04745767
Drug: TAK-994
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3 formulation.
Study: NCT04745767
Drug: TAK-994
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T4 formulation.
Study: NCT04745767
Drug: TAK-994
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T5 formulation.
Study: NCT06358638
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab is a cytotoxic monoclonal antibody (IgG1k) to CD38 and is commercially approved to treat multiple myeloma. CD38 is expressed on several types of blood cells including B-cells, antibody-secreting plasma blasts and plasma cells. As a result, it has been used to treat antibody-mediated diseases, including children with antibody-mediated cytopenias post-HCT.
Study: NCT06358638
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52.
Study: NCT06358638
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections as well as treat lymphangioleiomyomatosis and adults with perivascular epithelioid cell tumors.
Study: NCT05593627
Drug: Lithium Carbonate 250 MG Oral Tablet
Normalized name: lithium carbonate 250 MG Oral Tablet
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients undergoing heart valve surgery withcardiopulmonary bypass will take 250mg lithium carbonate
Study: NCT05584228
Drug: Azathioprine + infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination therapy using 2-2.5 mg/kg oral azathioprine plus subcutaneous infliximab
Study: NCT05942547
Drug: Diosmin
Normalized name: Diosmin
DrugBank: Diosmin (DB08995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diosmin 600mg twice daily
Study: NCT03999840
Drug: cemdisiran
Normalized name: Cemdisiran
DrugBank: Cemdisiran (DB16121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
Study: NCT06270433
Drug: Toludesvenlafaxine hydrochloride sustained-release tablets
Normalized name: bupropion
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
Study: NCT06270433
Drug: Desvenlafaxine succinate sustained-release tablets
Normalized name: desvenlafaxine succinate Extended Release Oral Tablet
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg orally once daily dosing for 8 weeks
Study: NCT04860141
Drug: Gabapentin 600mg
Normalized name: GABAPENTIN 600MG TAB
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will take gabapentin 600mg 2 hours prior to the procedure
Study: NCT05186545
Drug: surufatinib + fulvestrant + chidamide
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: surufatinib: 250 mg/d, QD PO; Fulvestrant: 500mg, im, Q4W; Chidamide 30mg, PO, BIW; Q4W
Study: NCT04759131
Drug: efanesoctocog alfa (BIVV001)
Normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: IV
Study: NCT02376751
Drug: sebelipase alfa
Normalized name: Sebelipase alfa
DrugBank: Sebelipase alfa (DB11563)
Approvals — FDA: yes, EMA: yes, PMDA: no